These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 19661355)

  • 1. Current and future options in the treatment of malignant ascites in ovarian cancer.
    Woopen H; Sehouli J
    Anticancer Res; 2009 Aug; 29(8):3353-9. PubMed ID: 19661355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pathogenesis and management of refractory malignant ascites].
    Saâda E; Follana P; Peyrade F; Mari V; François E
    Bull Cancer; 2011 Jun; 98(6):679-87. PubMed ID: 21636346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.
    Ströhlein MA; Heiss MM
    Future Oncol; 2010 Sep; 6(9):1387-94. PubMed ID: 20919824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma.
    Hirte HW; Miller D; Tonkin K; Findlay B; Capstick V; Murphy J; Buckman R; Carmichael J; Levine M; Hill W
    Gynecol Oncol; 1997 Jan; 64(1):80-7. PubMed ID: 8995552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer.
    Gotlieb WH; Feldman B; Feldman-Moran O; Zmira N; Kreizer D; Segal Y; Elran E; Ben-Baruch G
    Gynecol Oncol; 1998 Dec; 71(3):381-5. PubMed ID: 9887235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resolution of malignant ascites after intraperitoneal chemotherapy in women with carcinoma of the ovary.
    Lind SE; Cashavelly B; Fuller AF
    Surg Gynecol Obstet; 1988 Jun; 166(6):519-22. PubMed ID: 3375962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Laparoscopic intraperitoneal hyperthermic perfusion in palliation of malignant ascites. Case report].
    Graziosi L; Bugiantella W; Cavazzoni E; Donini A
    G Chir; 2009 May; 30(5):237-9. PubMed ID: 19505418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites.
    Easson AM; Bezjak A; Ross S; Wright JG
    Ann Surg Oncol; 2007 Aug; 14(8):2348-57. PubMed ID: 17505860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peritoneal catheter site metastasis in a patient with advanced ovarian cancer.
    Ramirez I; Bansal N; Hoffman M
    Am J Hosp Palliat Care; 2012 May; 29(3):241-2. PubMed ID: 21606122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Peritoneal carcinomatosis: new strategies for more efficacious treatment].
    Zanon C
    Recenti Prog Med; 2002 Sep; 93(9):457-62. PubMed ID: 12355981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer.
    Hamilton CA; Maxwell GL; Chernofsky MR; Bernstein SA; Farley JH; Rose GS
    Gynecol Oncol; 2008 Dec; 111(3):530-2. PubMed ID: 18561992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal catumaxomab therapy in a cirrhotic patient with malignant ascites due to urethelial carcinoma: a case report.
    Krawczyk M; Zimmermann S; Vidacek D; Lammert F
    Onkologie; 2012; 35(10):592-4. PubMed ID: 23038231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [What is the value of tumor debulking and intraperitoneal cytostasis].
    Laffer U; Knüsli C; Harder F
    Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir; 1990; ():205-10. PubMed ID: 1983552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of symptoms in terminally ill patients with ovarian carcinoma].
    Sun XG; Wu M; Ma SQ; Li CY; Jin LN; Shen K
    Zhonghua Fu Chan Ke Za Zhi; 2007 Mar; 42(3):192-5. PubMed ID: 17537307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant ascites in ovarian cancer and the role of targeted therapeutics.
    Smolle E; Taucher V; Haybaeck J
    Anticancer Res; 2014 Apr; 34(4):1553-61. PubMed ID: 24692682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoreductive surgery (cs) and hyperthermic intraperitoneal chemotherapy (hipec) in treatment of peritoneal surface malignances: report of a phase II clinical study.
    Asero S; Caruso M; Vallone N; Luciani AG; Lombardo V; Terranova G; Ettore G; Giannone G
    In Vivo; 2009; 23(4):645-7. PubMed ID: 19567402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature.
    Tsikouras P; Tsagias N; Pinidis P; Csorba R; Vrachnis N; Dafopoulos A; Bouchlariotou S; Liberis A; Teichmann AT; von Tempelhoff GF
    Arch Gynecol Obstet; 2013 Sep; 288(3):581-5. PubMed ID: 23644922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?
    Kobold S; Hegewisch-Becker S; Oechsle K; Jordan K; Bokemeyer C; Atanackovic D
    Oncologist; 2009 Dec; 14(12):1242-51. PubMed ID: 20008305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palliation of malignant ascites.
    Hodge C; Badgwell BD
    J Surg Oncol; 2019 Jul; 120(1):67-73. PubMed ID: 30903617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study.
    Berek JS; Edwards RP; Parker LP; DeMars LR; Herzog TJ; Lentz SS; Morris RT; Akerley WL; Holloway RW; Method MW; Plaxe SC; Walker JL; Friccius-Quecke H; Krasner CN
    Int J Gynecol Cancer; 2014 Nov; 24(9):1583-9. PubMed ID: 25254563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.